New IPO News | Tangji Medical Reapplies to Hong Kong Stock Exchange

According to a disclosure by the Hong Kong Stock Exchange on August 28, Hangzhou Tangji Medical Technology Co., Ltd. (referred to as: Tangji Medical) has submitted a listing application to the main board of the Hong Kong Stock Exchange, with ICBC International and Caitong International as its joint sponsors. The prospectus shows that Tangji Medical is a medical device company headquartered in China, focusing on providing innovative solutions for the treatment and comprehensive management of metabolic diseases. As of the final actual feasibility date, the company possesses (i) a core product, the gastric bypass stent system (GBS), which is a device for endoscopic duodenojejunostomy bypass (DJBL) suitable for obesity, and the company is expanding the approved indications for GBS to patients with lower BMI; (ii) two other products and a registered digital health management platform; and (iii) another 13 pipeline products.